Biotherapeutic agents in the treatment of infectious diarrhea.
Biotherapeutic agents offer unique advantages over traditional treatments for infectious diarrhea, and several have been shown to be effective (Table 4). These therapeutic microbial agents are most effective in types of infectious diseases that are associated with a disruption of the normal intestinal microecology (e.g., AAD, C. difficile disease). The impact of biotherapeutic agents on rotaviral diarrhea is of special clinical importance because this is the most common cause of pediatric diarrhea, and there is no defined treatment. Strong efforts need to be made to limit antibiotic exposure in children. Biotherapeutic agents offer a safe and effective nonantibiotic method of treating this important pathogen, especially after the withdrawal of a rotaviral vaccine from the market by the FDA. However, for many biotherapeutic agents, well-done, placebo-controlled trials still are lacking, and not all types of infectious diarrhea respond to these agents. Continued research in this innovative therapeutic area is warranted.
Elmer
G W
GW
Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington, USA. elmer@u.washington.edu
McFarland
L V
LV
D000328:Adult; D002675:Child, Preschool; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D016984:Enterococcus faecium; D006801:Humans; D007223:Infant; D007779:Lactobacillus acidophilus; D019936:Probiotics / Q000627:therapeutic use*; D012440:Saccharomyces; D014195:Travel